|apersy|

Value | Market Access | Commercialisation

Tag: GLP-1

  • Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe

    Weighing the Costs: Reimbursement of Anti-Obesity Medicines in the US and Europe

    With the global burden of obesity continuing to rise, the tension between established reimbursement rules, increased efficacy of new anti-obesity medicines and the need to tackle this population health issue is becoming more pronounced. Reimbursement policies for anti-obesity medications vary significantly by region and are driven by country-specific healthcare priorities, reimbursement policies and budget constraints,…